Market Overview

Analyst: Don't Expect Anika's Latest FDA Cleared Treatment To Impact 2018

Share:
Analyst: Don't Expect Anika's Latest FDA Cleared Treatment To Impact 2018
Related ANIK
The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price
The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering

Anika Therapeutics Inc (NASDAQ: ANIK) announced Wednesday it has received clearance from the U.S. Food and Drug Administration for its HA-based bone void filler, which is used to fill bone voids or defects of the skeletal system.

The Analyst

Barrington Research's Michael Petusky maintains an Outperform rating on Anika's stock with an unchanged $57 price target.

The Thesis

Anika's bone filler offers an invasive alternative versus the current standard of health that involves surgery, Petusky said in a note. As such, the company or a distribution partner will look to highlight this compelling feature as an advantage as it looks to position the product in the marketplace. The cost benefits of the bone repair treatment as opposed to bone grafting surgeries is significant and surgical procedures by default come with an increased risk of complication.

Anika believes the market size it can address is around $300 million, Petusky said. For the time being, the FDA's approval won't have any material revenue impact in 2018 and a 2019-2020 time frame is the earliest the new product could show any notable revenue impact. Nevertheless, the latest development represents "another positive step" in the company's goal of building out a meaningful regenerative medicine franchise.

Price Action

Shares of Anika were trading higher by around 0.2 percent late Thursday morning.

Related Links:

Markets Headed Higher In Early Going; Jobless Claims Remain Unchanged

Markets Mostly Higher; Live Ventures Shares Climb After Reporting 92% Rise in FY17 Revenue

Latest Ratings for ANIK

DateFirmActionFromTo
Jul 2018Barrington ResearchUpgradesMarket PerformOutperform
Jun 2018First AnalysisDowngradesOverweightEqual-Weight
May 2018Barrington ResearchUpgradesMarket PerformOutperform

View More Analyst Ratings for ANIK
View the Latest Analyst Ratings

Posted-In: Barrington Research Bone Void Filler Michael Petusky SurgeryAnalyst Color News FDA Analyst Ratings Best of Benzinga

 

Related Articles (ANIK)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ACBIKeefe Bruyette & WoodsUpgrades21.0
COTYBMO CapitalUpgrades12.0
ECCOppenheimerDowngrades0.0
VYGRRaymond JamesUpgrades0.0
ATNXJP MorganUpgrades15.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Why This Investor Sees Gain Capital As A Possible Winner From Bitcoin

8 Retail Stocks That Outperformed The Record-Breaking Holiday Shopping Season